Proteins and Microbiome: Beauty Giants Expand Portfolios in Premium Care
The industry is consolidating: Henkel buys Olaplex for $1.4 billion, and Reliance Retail acquires Priyanka Chopra's Anomaly. Formulas are booming with dermatological ingredients: niacinamide, peptides, and zinc for scalp health from Dove and Vichy.
The Gist: What's Really Happening
The professional and premium hair care market has set in motion the Great Consolidation. Henkel acquires Olaplex for $1.4 billion. Reliance Retail takes over Priyanka Chopra's Anomaly. Unilever recently bought K18. These are not isolated M&A events; they are links in a chain leading to an oligopoly of three global giants in the "scientific hair care" category.
Formulas are mimicking dermatology: niacinamide, peptides, zinc, glycerin, biomimetic technologies. Mass-market player Dove sits on the same shelf as pharmacy lines like Vichy Dercos, and the boundary between "skin care" and "hair care" is finally disappearing. We are witnessing not just growth in premium hair care, but a comprehensive dermatologization of the entire category—and a redistribution of market shares among three main power centers.
Insider insight: Independent "scientific" brands will not survive 18 months. Any startup that can prove efficacy through proteomics or biomimetics is ripe for acquisition. The reason is simple: the cost of clinical trials for hair products has doubled in 3 years. A solo player cannot survive without the financial muscle of Henkel, Unilever, or Reliance. The market is entering a phase of "patent portfolios," where patents on molecules and technologies are the new currency. And conglomerates are buying them up at an accelerating pace.
Timeline and Context
End of 2023. Unilever acquires K18—a biotech brand working on a peptide platform. This is the first loud signal: big players are entering "scientific hair care" in earnest.
March 2026. Henkel announces the acquisition of Olaplex Holdings for $1.4 billion—$2.06 per share, a 55% premium over market price. Advent International fully exits its investment. Kline + Company estimates Henkel's share of the global professional hair care market: 12%, solid second place after L'Oréal and ahead of Wella.
April 2026. L'Oréal launches Vichy Dercos in Southeast Asia with a focus on a "scalp-first" approach, selenium disulfide, salicylic acid, and AI diagnostics Scalp Consult Pro. Vichy announces a partnership with footballer Vitinha as a global ambassador—a male capture through sports.
Dove launches Dove Scalp + Hair Therapy—a collection with niacinamide, glycerin, and Dynazinc technology. Clinical tests: up to 10,000 additional hairs in the anagen phase, 89% of women see thicker, stronger hair.
Reliance Retail acquires Priyanka Chopra's Anomaly, taking over brand rights, digital assets, and intellectual property. The deal amount is undisclosed.
May 2026. We are here. The market is divided among three centers: Unilever (K18 + Dove), Henkel (Olaplex + Schwarzkopf + 12 professional brands in North America), L'Oréal (Vichy Dercos + Redken + Matrix + EverPure). Large independent assets in the "scientific hair care" segment are virtually exhausted.
Who Wins and Who Loses
Winners:
- Henkel. Solid second place in the global professional care market with a 12% share, ahead of Wella (10%). Olaplex fills Henkel's historically weak spot—the care category (shampoos, conditioners, treatments)—while Henkel is strong in styling and coloring. Plus 100+ patents from Olaplex on bond-building.
- Unilever. K18 + Dove Scalp bridges biotech luxury and mass market. Double-digit growth of Dove Hair in Q1 2026 confirms that dermatological legitimization yields direct commercial returns.
- L'Oréal. Vichy Dercos in Asia + AI diagnostics + sports marketing—the most global of the three strategies. Betting on the male audience through Vitinha opens a market that competitors are currently handling more weakly.
- Reliance Retail. Anomaly gives the Indian giant three assets at once: clean vegan formulas with global distribution, the recognizable face of Priyanka Chopra, and the Tira digital ecosystem for DTC sales. India becomes a priority market, with over 1.4 billion potential consumers.
- Mass-market consumers. Niacinamide, Dynazinc, and biomimetic peptides from Dove are technologies that just 3 years ago were only available in professional lines for $45 per bottle.
Losers:
- Independent "scientific" startups. After the acquisitions of Olaplex, K18, and Anomaly, the number of top-tier strategic buyers has shrunk to four. The entry price for a startup with a patent is now either straight to Henkel/Unilever/L'Oréal, or a sale at a lower multiple.
- Wella. Lost its solid second place and now has 10% of the market versus 12% for Henkel post-deal. Without a comparable asset in the "scientific" segment, it risks further falling behind.
- Traditional salon brands without a clinical portfolio. When Dove enters retail with "10,000 additional hairs" and 99% reduction in shedding, salon brands lacking their own research base lose the argument "professional means effective."
- Olaplex consumers who bought shares at IPO. Those who invested in 2021 at $21 per share get bought out at $2.06—a 90% loss. "Bag holders" from Reddit realize losses that turn the Olaplex story into a case study on DTC brand volatility.
What the Media Isn't Saying
1. Olaplex wasn't saved—it was methodically prepared for sale.
CEO Amanda Baldwin, who joined in 2024 from Supergoop!, implemented a strategy codenamed "Bonds and Beyond": repairing relationships with stylists, shedding the "discount" image, launching scalp products, settling class-action lawsuits. Wedbush Securities analysts directly call her task "cleaning house, prepared for a strategic buyer exit." This is not a business rescue. It's a capital improvement of an asset before sale. And the 55% premium over market price confirms the plan worked.
2. Dove is undercutting the salon business—and winning.
"Up to 10,000 additional hairs" is a clinical claim that previously only professional brands made. But Dove sells this at Boots, Superdrug, Tesco, and Amazon. The salon channel is losing its monopoly on "evidence-based efficacy." Retail becomes the #1 channel for dermatological hair care—and this is a structural shift that will change the distribution model forever.
3. Reliance Retail isn't buying a brand—it's buying a platform for the "Indian phenomenon."
The Indian market: over 1.4 billion people, hot climate, explosive middle-class growth, and specific scalp issues. Anomaly becomes the platform onto which Reliance will attach local innovations. This is not just M&A—it's the entry of a new global giant with resources comparable to Henkel and Unilever. In 3 years, Reliance could become the fourth power center in global hair care.
4. Scalp Consult Pro is L'Oréal's Trojan horse for data collection.
Vichy Dercos launches AI diagnostics not for customer convenience. It's a tool for collecting a massive dataset on scalp conditions across Southeast Asia. L'Oréal gains data that no independent brand can compete with. Every visit to Watsons for a diagnosis is a data point in a model that will predict scalp care trends 2 years ahead.
5. Competition among the three giants has shifted from "whose brand is louder" to "whose patent portfolio is thicker."
Olaplex has patents on bond-building. K18 on the peptide platform. Dove on Dynazinc. Vichy on formulas with selenium disulfide and Aminexil. This is no longer a war of marketing budgets. It's a patent war where the winner is determined not by ad share but by IP portfolio depth. Independent startups without patents drop out of the race before the first funding round.
Forecast: Next 30 Days and 90 Days
30 days (until June 8, 2026)
Henkel will begin integrating Olaplex into its professional brand portfolio—first reports of cross-category R&D projects between Olaplex and Schwarzkopf teams will emerge. Dove will scale the Scalp + Hair Therapy line to Asian markets, using the same retail channel that Vichy is currently developing. Vichy will activate the Vitinha campaign ahead of the 2026 FIFA World Cup—male "scalp care" will become a separate category in sports media. Reliance Retail will announce the launch of Anomaly products adapted for the Indian market via Tira and its 20,000 stores.
90 days (until August 7, 2026)
The FIFA World Cup will trigger the largest stress test in history for male hair care: Vichy and Dove Men+Care will roll out global campaigns. Olaplex under Henkel will present the first post-deal product—likely in the scalp treatment or anti-aging hair category. Kline + Company will release an updated Pro Hair Care ranking: it will become clear whether Henkel held its 12% or Wella regained ground. Reliance Retail will announce international expansion of Anomaly into North America and the UK—the Indian giant will enter the Western beauty market for the first time. Key signal: which of the three giants will announce the next "scientific" asset? The remaining large independent targets are few. The one who makes the next move will win the final round of the Great Consolidation.
— Editorial Team
